Research programme: ZFP-based therapeutics - Genentech/Sangamo Therapeutics
Latest Information Update: 13 Jan 2017
At a glance
- Originator Genentech
- Developer Genentech; Sangamo Therapeutics
- Class Proteins; Transcription factors
- Mechanism of Action DNA binding protein modulators; Genetic transcription modulators; Transcription factor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pain